Virtual Roundtable Discussion With Key Opinion Leaders in Psychiatry From Harvard and Imperial
The event will take place Wednesday, March 15, 2023 at 2:00 p.m. EDT.
Small Pharma announces further positive data from SPL026 Phase IIa trial in Major Depressive Disorder strengthening topline efficacy results
Statistically significant improvement in anxiety symptoms offers potential in indications beyond depression.
Small Pharma to present at Cowen’s 43rd Annual Healthcare Conference
The Phase I study will compare IV and IM routes of SPL028 administration.
What is deuteration? Small Pharma’s Phase I Trial with SPL028 – Dr Carol Routledge
Dr. Carol Routledge discusses our SPL028 Phase I healthy volunteer trial.
First Subject Dosed in Small Pharma’s First-in-Human Phase I Clinical Trial with SPL028
The Phase I study will compare IV and IM routes of SPL028 administration.
Small Pharma Announces Update on Intellectual Property Portfolio with Two New Patents Approved for Issue
Two new patents approved for issue bringing total to 16 granted patents.
Consultant Psychiatrist Dr. David Erritzoe discusses our Phase IIa Study
Dr. David Erritzoe shares what the results could mean for psychiatry.
Key data highlights from SPL026 Phase IIa trial – Dr. Carol Routledge
CMSO Dr. Carol Routledge gives an overview of the key data highlights.
Small Pharma Reports Fiscal Third Quarter 2023 Highlights
Positive top-line results from Phase IIa trial of SPL026 in MDD with new trials underway.
Small Pharma’s SPL026 Phase IIa trial results update – George Tziras, CEO
CEO George Tziras shares his thoughts on the impact of our Phase IIa trial results.